What if aging didn’t have to suck?”

That’s the slogan of a new Harvard University spinout that plans to put millions behind a hotly disputed rejuvenation discovery.

The startup, Elevian, which is based in San Francisco, says it intends to explore whether daily injections of a protein called GDF11 can promote “the body’s ability to restore itself” and eventually treat conditions including coronary artery disease, Alzheimer’s, and the muscle-loss condition sarcopenia.